Immunovant, Inc. has announced the topline results from two Phase 3 clinical trials evaluating batoclimab for the treatment of moderate-to-severe thyroid eye disease (TED). Unfortunately, both studies failed to meet their primary endpoint of a ≥2mm proptosis responder rate at Week 24, despite showing that patients experienced greater proptosis improvement during the initial high-dose treatment period compared to the subsequent low-dose phase. Importantly, safety profiles remained consistent with earlier studies, with no new safety concerns identified.

These findings are significant for the longevity and healthspan research community, particularly in the context of autoimmune diseases. The results underscore the complexities of developing effective therapies for conditions like TED, where deeper IgG suppression appears beneficial. The study also noted that hyperthyroid patients exhibited normalization of thyroid hormone levels similar to those observed in a previous Phase 2 study of batoclimab in Graves’ disease. This suggests that while the current trials did not achieve their goals, there may still be valuable insights to glean regarding the drug’s mechanism and potential applications.

The key takeaway from this development is Immunovant’s continued commitment to advancing IMVT-1402, an investigational FcRn blocker, across various autoimmune diseases, with Graves’ disease as a strategic priority. Upcoming topline data from potentially registrational studies in Graves’ disease are anticipated in 2027, indicating a sustained focus on addressing significant unmet medical needs in autoimmune conditions. As the field evolves, these insights into IgG suppression and therapeutic strategies will be crucial for researchers and clinicians alike.

Source: globenewswire.com